Picture of Eurofins Scientific SE logo

ERF — Eurofins Scientific SE News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

France's Eurofins H1 revenue up 2.5% on investment in laboratory network

France's Eurofins H1 revenue up 2.5% on investment in laboratory network


Overview

  • France laboratory testing firm's H1 revenue rose 2.5% year-on-year to €3.7 bln

  • Adjusted EBITDA margin for H1 expanded 130bps to 23.7%

  • Basic EPS for H1 grew 29% to €1.55, driven by operational improvements


Outlook

  • Eurofins targets mid-single-digit organic growth for FY 2026

  • Company expects adjusted EBITDA margin above FY 2025 level of 22.5% in 2026

  • Eurofins confirms FY 2027 adjusted EBITDA margin objective of 24%


Result Drivers

  • OPERATIONAL EFFICIENCIES - Margin expansion was driven by productivity gains, cost discipline, and closure of less profitable operations

  • INVESTMENT PROGRAMME BENEFITS - Ongoing investment in laboratory network and digitalisation supported operational improvements and profitability

  • STRONG CASH GENERATION - Higher cash conversion reflected lower capital expenditure and continued working capital discipline


Company press release: ID:nBw8SSs8da


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Adjusted Revenue

EUR 3.46 bln

H1 Adjusted Net Income

EUR 395 mln

H1 Adjusted EBITDA

EUR 877 mln

H1 Adjusted EBITDA Margin

23.7%


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 7 "hold" and 3 "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for Eurofins Scientific SE is €67.25, about 4.7% below its July 22 closing price of €70.58

  • The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 16 three months ago


Reuters Recommended Reads

  • July 23 - France's Sartorius Stedim Biotech H1 revenue rises on recurring consumables

  • July 22 - Lonza lifts margin target, repeats latter half of 2026 to be slower

  • July 21 - Danaher Q2 revenue, adjusted EPS beats on life sciences segment strength; raises outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Eurofins Scientific SE

See all news